Purpose of this Study
Study visits at week 0, 4, 6, 8, and 12.
Who Can Participate?
Eligibility
Participants with active AKC with symptoms of itching and eye redness
Age Range
18-65
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is testing an eye drop treatment to see if it is safe and works better than inactive eye drops. Participants will use one drop in each eye four times a day for 12 weeks. Researchers will compare the results between the study treatment and the inactive eye drops.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Adult Participants with Atopic Keratoconjunctivitis (AKC) - TRAK
Principal Investigator
Amol
Sura
Protocol Number
PRO00119397
NCT ID
NCT07395232
Phase
III
Enrollment Status
Open to Enrollment